Cumberland Pharmaceuticals (CPIX) Capital Expenditures Growth (3y) (2013 - 2026)
Cumberland Pharmaceuticals (CPIX) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | -4.39% |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | -11.01% |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | -0.22% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 34.19% |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | -8.00% |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 4.68% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | -7.72% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Cumberland Pharmaceuticals | 117.61 Mn | 113.74 Mn | - | -19.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -19.06% |
| Dec 31, 2025 | 98.13% |
| Sep 30, 2025 | -36.16% |
| Jun 30, 2025 | -42.21% |
| Mar 31, 2025 | 20.85% |
| Dec 31, 2024 | -36.81% |
| Sep 30, 2024 | -36.46% |
| Jun 30, 2024 | -21.91% |
| Mar 31, 2024 | 28.85% |
| Dec 31, 2023 | 2.18% |
| Sep 30, 2023 | 6.25% |
| Jun 30, 2023 | 36.87% |
| Mar 31, 2023 | 67.74% |
| Dec 31, 2022 | -57.73% |
| Sep 30, 2022 | 5.74% |
| Jun 30, 2022 | 30.61% |
| Mar 31, 2022 | -0.60% |
| Dec 31, 2021 | -68.29% |
| Sep 30, 2021 | 14.40% |
| Jun 30, 2021 | -25.74% |